317 related articles for article (PubMed ID: 23990376)
1. Inflammation: therapeutic targets for diabetic neuropathy.
Zhou J; Zhou S
Mol Neurobiol; 2014 Feb; 49(1):536-46. PubMed ID: 23990376
[TBL] [Abstract][Full Text] [Related]
2. Nrf2: a potential therapeutic target for diabetic neuropathy.
Kumar A; Mittal R
Inflammopharmacology; 2017 Aug; 25(4):393-402. PubMed ID: 28353124
[TBL] [Abstract][Full Text] [Related]
3. Ameliorative potential of rutin in combination with nimesulide in STZ model of diabetic neuropathy: targeting Nrf2/HO-1/NF-kB and COX signalling pathway.
Mittal R; Kumar A; Singh DP; Bishnoi M; Nag TC
Inflammopharmacology; 2018 Jun; 26(3):755-768. PubMed ID: 29094308
[TBL] [Abstract][Full Text] [Related]
4. Potential therapeutic effects of the simultaneous targeting of the Nrf2 and NF-κB pathways in diabetic neuropathy.
Ganesh Yerra V; Negi G; Sharma SS; Kumar A
Redox Biol; 2013 Aug; 1(1):394-7. PubMed ID: 24024177
[TBL] [Abstract][Full Text] [Related]
5. The neuroprotective effects of micronized PEA (PEA-m) formulation on diabetic peripheral neuropathy in mice.
Impellizzeri D; Peritore AF; Cordaro M; Gugliandolo E; Siracusa R; Crupi R; D'Amico R; Fusco R; Evangelista M; Cuzzocrea S; Di Paola R
FASEB J; 2019 Oct; 33(10):11364-11380. PubMed ID: 31344333
[TBL] [Abstract][Full Text] [Related]
6. Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy.
Navarro-González JF; Mora-Fernández C; Muros de Fuentes M; García-Pérez J
Nat Rev Nephrol; 2011 Jun; 7(6):327-40. PubMed ID: 21537349
[TBL] [Abstract][Full Text] [Related]
7. Heme oxygenase-1, a novel target for the treatment of diabetic complications: focus on diabetic peripheral neuropathy.
Negi G; Nakkina V; Kamble P; Sharma SS
Pharmacol Res; 2015 Dec; 102():158-67. PubMed ID: 26432957
[TBL] [Abstract][Full Text] [Related]
8. Diabetic neuropathy and nerve regeneration.
Yasuda H; Terada M; Maeda K; Kogawa S; Sanada M; Haneda M; Kashiwagi A; Kikkawa R
Prog Neurobiol; 2003 Mar; 69(4):229-85. PubMed ID: 12757748
[TBL] [Abstract][Full Text] [Related]
9. JSH-23 targets nuclear factor-kappa B and reverses various deficits in experimental diabetic neuropathy: effect on neuroinflammation and antioxidant defence.
Kumar A; Negi G; Sharma SS
Diabetes Obes Metab; 2011 Aug; 13(8):750-8. PubMed ID: 21447040
[TBL] [Abstract][Full Text] [Related]
10. Molecular mechanism of diabetic neuropathy and its pharmacotherapeutic targets.
Dewanjee S; Das S; Das AK; Bhattacharjee N; Dihingia A; Dua TK; Kalita J; Manna P
Eur J Pharmacol; 2018 Aug; 833():472-523. PubMed ID: 29966615
[TBL] [Abstract][Full Text] [Related]
11. Suppression of NF-κB and NF-κB regulated oxidative stress and neuroinflammation by BAY 11-7082 (IκB phosphorylation inhibitor) in experimental diabetic neuropathy.
Kumar A; Negi G; Sharma SS
Biochimie; 2012 May; 94(5):1158-65. PubMed ID: 22342224
[TBL] [Abstract][Full Text] [Related]
12. Pro-inflammatory mechanisms in diabetic neuropathy: focus on the nuclear factor kappa B pathway.
Cameron NE; Cotter MA
Curr Drug Targets; 2008 Jan; 9(1):60-7. PubMed ID: 18220713
[TBL] [Abstract][Full Text] [Related]
13. Sesamol suppresses neuro-inflammatory cascade in experimental model of diabetic neuropathy.
Chopra K; Tiwari V; Arora V; Kuhad A
J Pain; 2010 Oct; 11(10):950-7. PubMed ID: 20418182
[TBL] [Abstract][Full Text] [Related]
14. High-Mobility Group Box 1 Protein Signaling in Painful Diabetic Neuropathy.
Thakur V; Sadanandan J; Chattopadhyay M
Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32019145
[TBL] [Abstract][Full Text] [Related]
15. Anti-inflammatory effect of resveratrol attenuates the severity of diabetic neuropathy by activating the Nrf2 pathway.
Zhang W; Yu H; Lin Q; Liu X; Cheng Y; Deng B
Aging (Albany NY); 2021 Mar; 13(7):10659-10671. PubMed ID: 33770763
[TBL] [Abstract][Full Text] [Related]
16. Nrf2 and NF-κB modulation by sulforaphane counteracts multiple manifestations of diabetic neuropathy in rats and high glucose-induced changes.
Negi G; Kumar A; Sharma SS
Curr Neurovasc Res; 2011 Nov; 8(4):294-304. PubMed ID: 22023613
[TBL] [Abstract][Full Text] [Related]
17. GLP‑1R agonists ameliorate peripheral nerve dysfunction and inflammation via p38 MAPK/NF‑κB signaling pathways in streptozotocin‑induced diabetic rats.
Ma J; Shi M; Zhang X; Liu X; Chen J; Zhang R; Wang X; Zhang H
Int J Mol Med; 2018 May; 41(5):2977-2985. PubMed ID: 29484377
[TBL] [Abstract][Full Text] [Related]
18. Deciphering the Neuroprotective Role of Glucagon-like Peptide-1 Agonists in Diabetic Neuropathy: Current Perspective and Future Directions.
Mehta K; Behl T; Kumar A; Uddin MS; Zengin G; Arora S
Curr Protein Pept Sci; 2021; 22(1):4-18. PubMed ID: 33292149
[TBL] [Abstract][Full Text] [Related]
19. Inflammatory mediators in diabetic and non-diabetic lumbosacral radiculoplexus neuropathy.
Kawamura N; Dyck PJ; Schmeichel AM; Engelstad JK; Low PA; Dyck PJ
Acta Neuropathol; 2008 Feb; 115(2):231-9. PubMed ID: 18064475
[TBL] [Abstract][Full Text] [Related]
20. Evolving Insights into the Pathophysiology of Diabetic Neuropathy: Implications of Malfunctioning Glia and Discovery of Novel Therapeutic Targets.
Rahman MH; Jha MK; Suk K
Curr Pharm Des; 2016; 22(6):738-57. PubMed ID: 26635266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
